| Ytd | -40.81% | |
| 1y | 67.51% |
| Open | 0.80 | Prev Close | 0.79 | Low | 0.79 | High | 0.82 | Mkt Cap | 112.28M |
| Vol | 235.94K | Avg Vol | 743.68K | EPS | -0.15 | P/E | N/A | Forward P/E | -1.41 |
| Beta | 0.11 | Short Ratio | 0.36 | Inst. Own | 19.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 0.82 | 200-d Avg | 0.99 | 1yr Est | 11.50 |
RANI News
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on
~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform
SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI)
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) w
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:R
Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the
~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion
SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI),
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday'
SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a c
~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietar
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a cl
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeut
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the a
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of ob
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeut
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therape
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-valu
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therape
Rani Therapeutics (NASDAQ: RANI - Get Free Report) and Milestone Pharmaceuticals (NASDAQ: MIST - Get
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therape
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report) has earned an average recommendati
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu
Biotech stocks have trailed the broader market this year, but more names are starting to show streng
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session
